Akebia Therapeutics (AKBA) Common Equity (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Common Equity data on file, last reported at $27.4 million in Q1 2026.

• On a quarterly basis, Common Equity rose 11.37% year-over-year to $27.4 million in Q1 2026; TTM through Mar 2026 was $27.4 million, a 11.37% increase from a year earlier, with the FY2025 full-year figure at $32.6 million, up 166.3% from the prior year.
• Common Equity for Q1 2026 stood at $27.4 million, down from $32.6 million in the prior quarter.
• Over the last five years, Common Equity for AKBA reached as high as $58.9 million in Q2 2022 and fell as low as -$50.4 million in Q3 2024.
• Historically, Common Equity has averaged -$1.5 million across 5 years, with a median of $5.2 million in 2022.
• Across the five-year window, Common Equity sank 684.78% in 2023 and surged 190.18% in 2025, its largest moves.
• Year by year, Common Equity stood at $5.2 million in 2022, then sank by 684.78% to -$30.6 million in 2023, then plunged by 60.82% to -$49.2 million in 2024, then jumped by 166.3% to $32.6 million in 2025, then slipped by 16.05% to $27.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $27.4 million in Q1 2026, $32.6 million in Q4 2025, and $41.6 million in Q3 2025.